# US 9,517,234 B2 · Tetrandrine family pharmaceutical formulations and method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,234 B2
- Document ID: US9517234B2
- Status: Granted
- Kind: B2
- Application number: 14/199,235
- Filed: 2014-03-06
- Published: 2014-09-18
- Granted: 2016-12-13
- Earliest claimed: 2013-03-15
- Assignees: CBA Pharma, Inc.
- Applicants: CBA Pharma, Inc.
- Inventors: Ron D. Carroll
- Web page: https://patentgrep.com/patent/US9517234B2

## CPC

- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.

## Claims

### Claim 1

A pharmaceutical formulation comprising:
the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, colloidal silicone dioxide, sodium lauryl sulfate and magnesium stearate in the following amounts:
50 mg d-tetrandrine di-acid salt,
384 mg Pregelatinized Starch NF (Starch 1500),
4.4 mg Colloidal Silicon Dioxide (Cab-O-Sil M5),
0.4 mg Sodium Lauryl Sulfate NF, and
1 mg Magnesium Stearate NF.

### Claim 2

A pharmaceutical formulation comprising:
the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, colloidal silicone dioxide, sodium lauryl sulfate and magnesium stearate in the following amounts:
200 mg d-tetrandrine di-acid salt,
25.2 mg Pregelatinized Starch 1500 NF,
1.5 mg Silicon Dioxide USP,
0.25 mg Sodium Lauryl Sulfate NF, and
1.25 mg Magnesium Stearate USP.

### Claim 3

A pharmaceutical formulation comprising:
the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, microcrystalline cellulose, sodium lauryl sulfate and magnesium stearate in the following amounts:
100 mg d-tetrandrine di-acid salt,
70 mg microcrystalline cellulose,
0.2 mg sodium lauryl sulfate, and
0.6 mg magnesium stearate.